



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/960,643	09/20/2001	Thillainathan Yoganathan	KINE024	5240

24353 7590 05/09/2003

BOZICEVIC, FIELD & FRANCIS LLP
200 MIDDLEFIELD RD
SUITE 200
MENLO PARK, CA 94025

EXAMINER

SHUKLA, RAM R

ART UNIT

PAPER NUMBER

1632

DATE MAILED: 05/09/2003

10

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/960,643

Applicant(s)

YOGANATHAN ET AL.

Examiner

Ram R. Shukla

Art Unit

1632

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 21 January 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-10 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-3 and 5-10 is/are rejected.
- 7) ☒ Claim(s) 4 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 20 September 2001 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) <u>6</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. Applicant's election of the invention of groups I, claims 1-10 in Paper No. 9 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).
2. Claims 11-15 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in Paper No. 9.
3. Claims 11-15 have been cancelled.
4. Claims 1-10 are pending and under consideration.

Priority

5. An application in which the benefits of an earlier application are desired must contain a specific reference to the prior application(s) in the first sentence of the specification of in an application data sheet (37 CFR 1.78(a)(2) and (a)(5)). The specific reference to any prior nonprovisional application must include the relationship (i.e., continuation, divisional, or continuation-in-part) between the applications except when the reference is to a prior application of a CPA assigned the same application number.

Claim Rejections - 35 USC § 112

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claims 1, 2 and 6-10 rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably

convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

When the claims are analyzed in light of the specification, instant invention encompasses any isolated nucleic acid that encodes a mammalian CaMk-X1 protein and hybridizes under given stringent condition to the sequence of SEQ ID NO 1, such nucleic acids encompass any mammalian CaMk-X1 protein or variants. However, the specification discloses only SEQ ID NO 1 that encodes the polypeptide disclosed in SEQ ID NO 2. In analyzing whether the written description requirement is met for genus claims, it is first determined whether a representative number of species have been described by their complete structure. In the instant case, SEQ ID NO 1 is the only species whose complete structure is disclosed. The specification does not provide any disclosure as to what would have been the structure of the species encompassed by the claimed invention.

Next, then, it is determined whether a representative number of species have been sufficiently described by other relevant identifying characteristics (i.e. other than nucleotide sequence), specific features and functional attributes that would distinguish different members of the claimed genus. In the instant case, the only other identifying characteristic is the sequence encodes a mammalian CaMK-X1 protein and hybridizes with SEQ ID NO 1. In regard to polynucleotides from species other than humans, it is noted that the specification does not provide any disclosure whether these sequences from other species would have had same characteristics or would have had additional characteristics or properties.

Applicants' attention is directed to the decision in *In re Shokal*, 113 USPQ 283 (CCPA 1957) wherein is stated:

It appears to be well settled that a single species can rarely, if ever, afford sufficient support for a generic claim. *In re Soll*, 25 C.C.P.A. (Patents) 1309, 97 F.2d 623, 38 USPQ 189; *In re Wahlforss et al.*, 28 C.C.P.A. (Patents) 867, 117 F.2d 270, 48 USPQ 397. The decisions do not however fix any definite number of species which will establish completion of a generic invention and it seems evident therefrom that such number will vary, depending on the circumstances of particular cases. Thus, in the case of small genus such as the halogens, consisting of four species, a reduction to practice of three, or perhaps even

Art Unit: 1632

two, might serve to complete the generic invention, while in the case of a genus comprising hundreds of species, a considerably larger number of reductions to practice would probably be necessary.

In conclusion, this limited information is not deemed sufficient to reasonably convey to one skilled in the art that applicant is in possession of cDNAs besides SEQ ID No 1 that encodes the amino acid sequences disclosed in SEQ ID NO 2, at the time the application was filed. Thus it is concluded that the written description requirement is not satisfied for the claimed genus.

8. Claims 1-3 and 6-10 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for an isolated nucleic acid that comprises the sequence set forth in SEQ ID NO 1 and that encodes the amino acid sequence of SEQ ID NO 2, a plasmid or a vector comprising the nucleic acid sequence, does not reasonably provide enablement for other claimed embodiments. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

The instant invention encompasses any isolated nucleic acid that encodes a mammalian CaMk-X1 protein and hybridizes under given stringent condition to the sequence of SEQ ID NO 1, such nucleic acids encompass any mammalian CaMk-X1 protein or variants.

While determining whether a specification is enabling, one considers whether the claimed invention provides sufficient guidance to make and use the claimed invention, if not, whether an artisan would have required undue experimentation to make and use the claimed invention and whether working examples have been provided. When determining whether a specification meets the enablement requirements, some of the factors that need to be analyzed are: the breadth of the claims, the nature of the invention, the state of the prior art, the level of one of ordinary skill, the level of predictability in the art, the amount of direction provided by the inventor, the existence of working examples, and whether the quantity of any necessary experimentation to make or use the invention based on the content

of the disclosure is "undue" (In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988)).

Furthermore, USPTO does not have laboratory facilities to test if an invention will function as claimed when working examples are not disclosed in the specification, therefore, enablement issues are raised and discussed based on the state of knowledge pertinent to an art at the time of the invention, therefore skepticism raised in the enablement rejections are those raised in the art by artisans of expertise.

First, the specification is not enabling for all the claimed polynucleotides of claims 1 comprising said nucleic acids because the specification only teaches a polynucleotide of SEQ ID NO 1 that encodes the polypeptide of SEQ ID NO 2. The issue is: how would an artisan make the nucleic acids as recited in claim 1 that would encode a mammalian CaMk-X1 protein. The specification does not teach how to make nucleic acids as recited in claim 1 that would encode a mammalian CaMk-X1 protein and would hybridize to SEQ ID NO 1 under conditions recited. The proteins would include mutants produced by deletion, substitution, and addition in the wild type polynucleotides of SEQ ID NO 1. It is recognized in the prior art that the function of a protein depends on the sequence of its amino acids in a certain pattern, conformation of the protein due to the amino acid sequence, and the functional properties of the different parts of the protein (see second paragraph in Rudinger J in Peptide Hormones. Editor Parsons JA. Pages 1-7, 1976, University Park Press, Baltimore). Rudinger further add, "The significance of particular amino acids and sequences for different aspects of biological activity can not be predicted *a priori* but must be determined from case to case by painstaking experimental study" (see conclusion on page 6). The specification does not teach which changes in the nucleotide sequence of SEQ ID NO 1 or 3 would encode a amino acid sequences that would retain the function of the human Kv4.3 protein. The specification does not teach how will the sequences of different mammalian species are related. The specification does not teach how to use a nucleic acid that would have encoded a protein which was derived from the protein of SEQ ID NO 2 but did

not have the function of the starting protein. Alternatively, the specification does not teach how would an artisan have made a polynucleotide that would have encoded a protein in which every other amino acids would have been changed but the protein would have retained the function of the starting protein.

While it is known that many amino acid substitutions are generally possible in any given protein, the positions within the protein's sequence where such amino acid substitutions can be made with a reasonable expectation of success are limited. Certain positions in the sequence are critical to the protein's structure/function relationship, e.g. such as various sites or regions where the biological activity resides or regions directly involved in binding, stability, or catalysis; and in providing the correct three-dimensional spatial orientation for biologically active or binding sites, or for sites which represent other characteristics/properties of the protein. These or other regions may also be critical determinants of antigenicity of the protein of interest. These regions can tolerate only relatively conservative substitutions or no substitutions (see Bowie et al., 1990. Science, Vol. 247, pp. 1306-1310, especially p. 1306, column 2, paragraph 2; and see Ngo et al, The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al. (ed.), pages 433&492-495). Applicant has provided little or no guidance beyond the mere presentation of sequence data to enable one of ordinary skill in the art to determine, without undue experimentation, the positions in the protein which are tolerant amino acid substitutions and the nature and extent of changes that can be made in these positions in order to obtain protein that retain function. Such a definition might also read on previously characterized proteins, or alternatively, might include proteins with additional functions or activities neither envisioned nor enabled by applicants in the current invention.

As set forth in *In re Fisher*, 166 USPQ 18 (CCPA 1970), compliance with 35 USC 112, first paragraph requires:

that scope of claims must bear a reasonable correlation to scope of enablement provided by specification to persons of ordinary skill in the art; in cases involving predictable factors, such as mechanical or electrical elements, a single embodiment provides broad enablement in the sense that,

Art Unit: 1632

once imagined, other embodiments can be made without difficulty and their performance characteristics predicted by resort to known scientific laws; in cases involving unpredictable factors, such as most chemical reactions and physiological activity, scope of enablement varies inversely with degree of unpredictability of factors involved.

Additionally, if the specification is not enabling for the claimed nucleic acids, it would not be enabling for the claimed vectors (claims 6-10) because if an artisan did not know how to make and use the nucleic acids, how would an artisan know, how to use such vectors or organisms that comprised such nucleic acids or vectors.

Therefore, the specification does not provide sufficient guidance to make and use the claimed invention commensurate with the scope of the claims and therefore, limiting the scope of the claimed invention to an isolated nucleic acid that comprises the sequence set forth in SEQ ID NO 1 and that encodes the amino acid sequence of SEQ ID NO 2, a plasmid or a vector comprising the nucleic acid sequence is proper.

Claim Rejections - 35 USC § 102

9. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of

the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

10. Claim 5 is rejected under 35 U.S.C. 102(b) as being anticipated by Grafham et al (GenEmbl Accession No. ALO23754, Locus HS272L16, 23-11-1999).

This art teaches a nucleic acid sequence which has 100% sequence similarity with nt 1533-2437 of SEQ ID NO 1 of the instant application (see the enclosed sequence search results).

Accordingly, the invention of claim 5 is anticipated by Grafham et al.

11. Claims 1-3 and 5-10 rejected under 35 U.S.C. 102(e) as being anticipated by Tang et al (US 2002/0197679, pub date 12-26-02, effective filing date 1-20-00 and WO 200153312-A1).

Tang et al teaches a nucleic acid (SEQ ID NO 4) that has 100% identity over nt 12 -1958 of SEQ ID NO 1 of the instant invention has almost 100% sequence similarity to nt 7-1956 of accession no. AAI60703. Since the sequence similarity is in the coding region and the nucleic acid encodes the amino acid sequence of SEQ ID NO 2 (see the enclosed sequence search results). The art teaches that the nucleic acid can be inserted in different types of vectors and plasmids (see page 7, paragraph 0084-0089).

Accordingly, the invention of claims 1-3 and 5-10 is anticipated by Tang et al.

12. Claims 1-3 and 5-7 are rejected under 35 U.S.C. 102(b) as being anticipated by Rhodes et al (GenEmbl Accession No. AL049688, 4-21-1999).

Rhodes et al teaches a nucleic acid that encodes the protein of SEQ ID NO 2 of the instant application. The nucleic acid was isolated from a cDNA expression library. Accordingly, it is cloned in a vector that expresses the protein and thus have promoter and is a plasmid.


Accordingly, claims 1-3 and 5-7 are anticipated by Rhodes et al.

Art Unit: 1632

13. Claim 4 is objected to because it is dependent on a rejected claim. If it was written in an independent form it could be allowable.

14. No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ram R. Shukla whose telephone number is (703) 305-1677. The examiner can normally be reached on Monday through Friday from 7:30 am to 4:00 p.m. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached on (703) 305-4051. The fax phone number for this Group is (703) 308-4242. The after-final fax number is (703) 87209307. Any inquiry of a general nature, formal matters or relating to the status of this application or proceeding should be directed to the William Phillips whose telephone number is (703) 305-3413.



RAM SHUKLA
PRIMARY EXAMINER

Ram R. Shukla, Ph.D.
Primary Examiner
Art Unit 1632